Cargando…
Impact of statins and ACE inhibitors on mortality after COPD exacerbations
BACKGROUND: The purpose of our study was to examine the association of prior outpatient use of statins and angiotensin converting enzyme (ACE) inhibitors on mortality for subjects ≥ 65 years of age hospitalized with acute COPD exacerbations. METHODS: We conducted a retrospective national cohort stud...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697974/ https://www.ncbi.nlm.nih.gov/pubmed/19493329 http://dx.doi.org/10.1186/1465-9921-10-45 |
_version_ | 1782168353965604864 |
---|---|
author | Mortensen, Eric M Copeland, Laurel A Pugh, Mary Jo V Restrepo, Marcos I de Molina, Rosa Malo Nakashima, Brandy Anzueto, Antonio |
author_facet | Mortensen, Eric M Copeland, Laurel A Pugh, Mary Jo V Restrepo, Marcos I de Molina, Rosa Malo Nakashima, Brandy Anzueto, Antonio |
author_sort | Mortensen, Eric M |
collection | PubMed |
description | BACKGROUND: The purpose of our study was to examine the association of prior outpatient use of statins and angiotensin converting enzyme (ACE) inhibitors on mortality for subjects ≥ 65 years of age hospitalized with acute COPD exacerbations. METHODS: We conducted a retrospective national cohort study using Veterans Affairs administrative data including subjects ≥65 years of age hospitalized with a COPD exacerbation. Our primary analysis was a multilevel model with the dependent variable of 90-day mortality and hospital as a random effect, controlling for preexisting comorbid conditions, demographics, and other medications prescribed. RESULTS: We identified 11,212 subjects with a mean age of 74.0 years, 98% were male, and 12.4% of subjects died within 90-days of hospital presentation. In this cohort, 20.3% of subjects were using statins, 32.0% were using ACE inhibitors or angiotensin II receptor blockers (ARB). After adjusting for potential confounders, current statin use (odds ratio 0.51, 95% confidence interval 0.40–0.64) and ACE inhibitor/ARB use (0.55, 0.46–0.66) were significantly associated with decreased 90-day mortality. CONCLUSION: Use of statins and ACE inhibitors prior to admission is associated with decreased mortality in subjects hospitalized with a COPD exacerbation. Randomized controlled trials are needed to examine whether the use of these medications are protective for those patients with COPD exacerbations. |
format | Text |
id | pubmed-2697974 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-26979742009-06-18 Impact of statins and ACE inhibitors on mortality after COPD exacerbations Mortensen, Eric M Copeland, Laurel A Pugh, Mary Jo V Restrepo, Marcos I de Molina, Rosa Malo Nakashima, Brandy Anzueto, Antonio Respir Res Research BACKGROUND: The purpose of our study was to examine the association of prior outpatient use of statins and angiotensin converting enzyme (ACE) inhibitors on mortality for subjects ≥ 65 years of age hospitalized with acute COPD exacerbations. METHODS: We conducted a retrospective national cohort study using Veterans Affairs administrative data including subjects ≥65 years of age hospitalized with a COPD exacerbation. Our primary analysis was a multilevel model with the dependent variable of 90-day mortality and hospital as a random effect, controlling for preexisting comorbid conditions, demographics, and other medications prescribed. RESULTS: We identified 11,212 subjects with a mean age of 74.0 years, 98% were male, and 12.4% of subjects died within 90-days of hospital presentation. In this cohort, 20.3% of subjects were using statins, 32.0% were using ACE inhibitors or angiotensin II receptor blockers (ARB). After adjusting for potential confounders, current statin use (odds ratio 0.51, 95% confidence interval 0.40–0.64) and ACE inhibitor/ARB use (0.55, 0.46–0.66) were significantly associated with decreased 90-day mortality. CONCLUSION: Use of statins and ACE inhibitors prior to admission is associated with decreased mortality in subjects hospitalized with a COPD exacerbation. Randomized controlled trials are needed to examine whether the use of these medications are protective for those patients with COPD exacerbations. BioMed Central 2009 2009-06-03 /pmc/articles/PMC2697974/ /pubmed/19493329 http://dx.doi.org/10.1186/1465-9921-10-45 Text en Copyright © 2009 Mortensen et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Mortensen, Eric M Copeland, Laurel A Pugh, Mary Jo V Restrepo, Marcos I de Molina, Rosa Malo Nakashima, Brandy Anzueto, Antonio Impact of statins and ACE inhibitors on mortality after COPD exacerbations |
title | Impact of statins and ACE inhibitors on mortality after COPD exacerbations |
title_full | Impact of statins and ACE inhibitors on mortality after COPD exacerbations |
title_fullStr | Impact of statins and ACE inhibitors on mortality after COPD exacerbations |
title_full_unstemmed | Impact of statins and ACE inhibitors on mortality after COPD exacerbations |
title_short | Impact of statins and ACE inhibitors on mortality after COPD exacerbations |
title_sort | impact of statins and ace inhibitors on mortality after copd exacerbations |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697974/ https://www.ncbi.nlm.nih.gov/pubmed/19493329 http://dx.doi.org/10.1186/1465-9921-10-45 |
work_keys_str_mv | AT mortensenericm impactofstatinsandaceinhibitorsonmortalityaftercopdexacerbations AT copelandlaurela impactofstatinsandaceinhibitorsonmortalityaftercopdexacerbations AT pughmaryjov impactofstatinsandaceinhibitorsonmortalityaftercopdexacerbations AT restrepomarcosi impactofstatinsandaceinhibitorsonmortalityaftercopdexacerbations AT demolinarosamalo impactofstatinsandaceinhibitorsonmortalityaftercopdexacerbations AT nakashimabrandy impactofstatinsandaceinhibitorsonmortalityaftercopdexacerbations AT anzuetoantonio impactofstatinsandaceinhibitorsonmortalityaftercopdexacerbations |